Navigation Links
Spike in Use of Popular Reflux Drug to Treat Infants Causes Alarm
Date:5/3/2010

Reglan, metoclopramide never approved for use in infants

HOUSTON, May 3 /PRNewswire-USNewswire/ -- Recently, researchers have observed a disturbing trend in neonatal units across the country:  doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants.

Reglan (metoclopramide) was approved for short term use – no longer than three months – by the Food & Drug Administration in 1979 to treat various gastrointestinal disorders.  But in 2009, the FDA issued a black box warning, the strongest of its kind, for the drug and its generic forms, stating that the medication had "been linked to tardive dyskinesia."  In fact, Reglan (metoclopramide) has been identified as the leading cause of TD among patients with the disorder in the United States.

The increase in its use in neonatal units began about a decade ago, when the only motility agent approved for use in infants was pulled from the market for safety concerns.  It has continued to grow each year.  While those at highest risk of developing TD are women and the elderly, there are very serious concerns about the safety of treating babies with Reglan (metoclopramide), as there has never been any significant research done on the drug's effects on infant populations.  

"Although the FDA issued its black box warning last year," said Scott Nabers, of Blizzard, McCarthy & Nabers, which represents dozens of patients disabled by Reglan, "many doctors and patients are still not aware of the significant risks associated with its use.  Because Reglan has been on the market for over 30 years, many physicians assume the drug is safe and prescribe it for various off-label uses.  Perhaps the most troubling of these is its use to treat premature babies whose bodies are already extremely frail."

Blizzard, McCarthy & Nabers recently launched the website ReglanJustice.com to provide consumers with critical information about the risks associated with Reglan (metoclopramide).

Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. 


'/>"/>
SOURCE Blizzard, McCarthy & Nabers, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
2. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
3. Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
4. Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
5. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
6. Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa
7. Popular Energy Drinks Cause Tooth Erosion
8. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
9. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
10. New Incision-Less Procedure for REFLUX - Experts Consider it to Be Gold Standard for REFLUX
11. Medical World Recognises New Therapy for Reflux Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  From the company that brought a ... fourteen years ago, comes a new line of companion animal pet ... world leader in equine first aid, has developed two sizes of ... USA , Inc. Featuring a small and a ... company and rodeo family, is not a newcomer to working with ...
(Date:1/17/2017)... , Jan. 17, 2017  OrthoAccel ® ... Orthodontics (JCO) has published "The Effect of Vibration ... patients. Conducted by Dr. S. Jay Bowman , ... Class II malocclusions, AcceleDent,s SoftPulse Technology ® speeds ... while also reducing the number of days to move ...
(Date:1/17/2017)... Research and Markets has announced the addition ... report to their offering. ... The global fluoropolymer market in the healthcare industry to ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has ... industry experts. The report covers the market landscape and its growth ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... education for EMS and firefighting professionals, has released four new continuing education courses ... courses are taught live in an online classroom and meet the requirements of ...
(Date:1/17/2017)... Smithtown, New York (PRWEB) , ... January 17, ... ... provider network – SightMD – will lecture to primary eye care practitioners on ... vision-threatening conditions at the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye ...
(Date:1/17/2017)... ... 17, 2017 , ... SensorInsight ®, an Internet of ... the U.S.A. to offer Internet of Things (IoT) solutions based on Libelium ... deployments such as monitoring solutions used to detect potentially hazardous conditions in urban ...
(Date:1/17/2017)... ... 2017 , ... Wettstein Agencies, a Denver area firm that ... central Colorado, is joining local nonprofit Aurora Warms The Night to provide services ... is committed to breaking the cycle of homelessness and poverty affecting a growing ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Livionex, Inc., a ... of a double blind clinical study for its dental gel that shows significant reduction ... brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute ...
Breaking Medicine News(10 mins):